Novartis' Complement Inhibitor Fabhalta Approved for IgAN

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Novartis for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.